PE20130217A1 - Composiciones farmaceuticas y metodos para su elaboracion - Google Patents
Composiciones farmaceuticas y metodos para su elaboracionInfo
- Publication number
- PE20130217A1 PE20130217A1 PE2012002115A PE2012002115A PE20130217A1 PE 20130217 A1 PE20130217 A1 PE 20130217A1 PE 2012002115 A PE2012002115 A PE 2012002115A PE 2012002115 A PE2012002115 A PE 2012002115A PE 20130217 A1 PE20130217 A1 PE 20130217A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- amount
- preparation
- methods
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000010979 pH adjustment Methods 0.000 abstract 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 abstract 1
- 229960000639 pazopanib Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UNA SAL DE ADICION DE ACIDO DE PAZOPANIB EN UNA CANTIDAD DE 10 MG DE BASE LIBRE POR ML DE LA COMPOSICION; B) UNA CICLODEXTRINA MODIFICADA TAL COMO SULFO-BUTIL-ETER DE B-CICLODEXTRINA EN UNA CANTIDAD DE 2.0 A 13.0% EN PESO DE LA COMPOSICION; C) UN AGENTE DE AJUSTE DEL PH QUE PROPORCIONE UN RANGO DE PH DE 3.5 A 5.7 TAL COMO HIDROXIDO DE SODIO, ACIDO CLORHIDRICO Y COMBINACIONES DE LOS MISMOS; D) UN AGENTE DE AJUSTE DE TONICIDAD PARA PROPORCIONAR UNA OSMOLARIDAD DE 200 A 400 mOsm; Y E) AGUA. DICHA COMPOSICION ES UNA COMPOSICION OFTALMICA ESTABLE UTIL EN EL TRATAMIENTO DE DEGENERACION MACULAR RELACIONADA CON LA EDAD
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33171510P | 2010-05-05 | 2010-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130217A1 true PE20130217A1 (es) | 2013-03-21 |
Family
ID=44851507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002115A PE20130217A1 (es) | 2010-05-05 | 2011-05-05 | Composiciones farmaceuticas y metodos para su elaboracion |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20110281901A1 (es) |
| EP (1) | EP2566331B1 (es) |
| JP (1) | JP5835717B2 (es) |
| KR (1) | KR20130071434A (es) |
| CN (1) | CN102970871A (es) |
| AR (1) | AR081364A1 (es) |
| AU (1) | AU2011247995B2 (es) |
| BR (1) | BR112012028291A2 (es) |
| CA (1) | CA2798386A1 (es) |
| CL (1) | CL2012003075A1 (es) |
| CO (1) | CO6640262A2 (es) |
| CR (1) | CR20120556A (es) |
| DO (1) | DOP2012000281A (es) |
| EA (1) | EA201291168A1 (es) |
| ES (1) | ES2519615T3 (es) |
| IL (1) | IL222751A0 (es) |
| MA (1) | MA34286B1 (es) |
| MX (1) | MX2012012837A (es) |
| NZ (1) | NZ603411A (es) |
| PE (1) | PE20130217A1 (es) |
| PH (1) | PH12012502159A1 (es) |
| SG (1) | SG185087A1 (es) |
| TW (1) | TW201206908A (es) |
| UY (1) | UY33367A (es) |
| WO (1) | WO2011140343A1 (es) |
| ZA (1) | ZA201208265B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| TW201206908A (en) * | 2010-05-05 | 2012-02-16 | Glaxo Wellcome Mfg Pte Ltd | Pharmaceutical compositions and methods of making same |
| CN105435338B (zh) | 2010-08-05 | 2019-03-26 | 弗赛特影像4股份有限公司 | 用于药物输送的注入器装置和方法 |
| CA2818612C (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| DK2755600T3 (da) | 2011-09-16 | 2021-05-03 | Forsight Vision4 Inc | Fluidudvekslingsindretning |
| CN104244952A (zh) * | 2012-02-17 | 2014-12-24 | 药品循环公司 | 组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途 |
| JP2015513864A (ja) * | 2012-03-08 | 2015-05-14 | サムスン エレクトロニクス カンパニー リミテッド | 無線通信システムでサービスを制御するための方法 |
| CA2905496A1 (en) * | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| US9526654B2 (en) | 2013-03-28 | 2016-12-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
| PT3039424T (pt) | 2013-08-28 | 2020-09-03 | Crown Bioscience Inc Taicang | Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo |
| SG11201700943TA (en) * | 2014-08-08 | 2017-03-30 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| CN114587774B (zh) | 2014-11-10 | 2024-07-19 | 弗赛特影像4股份有限公司 | 治疗眼睛的系统 |
| US11129900B2 (en) | 2014-12-25 | 2021-09-28 | Kyoto University | Cytophilic peptide-fused high-density lipoprotein, and delivery of drug to posterior segment of eye by ocular installation of said fusion |
| WO2017176886A1 (en) | 2016-04-05 | 2017-10-12 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
| WO2018192416A1 (en) * | 2017-04-17 | 2018-10-25 | National Institute Of Biological Sciences, Beijing | Treating Male Senescence |
| TWI770246B (zh) * | 2017-08-02 | 2022-07-11 | 昊運股份有限公司 | 新穎化合物及包含其之醫藥組成物 |
| DK4249069T3 (da) * | 2018-06-07 | 2025-12-22 | Pfizer | Vandig formulering omfattende 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| CN113350351A (zh) * | 2020-03-13 | 2021-09-07 | 青晓制药公司 | 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用 |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
| US20240050429A1 (en) * | 2022-08-10 | 2024-02-15 | Qx Therapeutics, Inc. | Pazopanib pharmaceutical composition, injection and preparation method and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
| US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| CA2631173A1 (en) * | 2005-11-29 | 2007-06-07 | Smithkline Beecham Corporation | Treatment method |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| EP2012788A4 (en) * | 2006-04-18 | 2010-05-26 | Ekr Therapeutics Inc | PREPARED USE-READY INTRAVENOUS BOLUSA COMPOSITIONS AND USE METHOD |
| US20090155176A1 (en) * | 2007-10-19 | 2009-06-18 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
| EP2252616B1 (en) * | 2008-01-30 | 2014-07-23 | Genentech, Inc. | Pyrazolopyrimidine pi3k inhibitor compounds and methods of use |
| CN102573477A (zh) * | 2009-07-16 | 2012-07-11 | 葛兰素惠尔康制造业私人有限公司 | 治疗方法 |
| WO2011039648A1 (en) * | 2009-09-30 | 2011-04-07 | Glaxo Wellcome Manufacturing Pte Ltd. | Methods of administration and treatment |
| TW201201808A (en) * | 2010-01-06 | 2012-01-16 | Glaxo Wellcome Mfg Pte Ltd | Treatment method |
| TW201206908A (en) * | 2010-05-05 | 2012-02-16 | Glaxo Wellcome Mfg Pte Ltd | Pharmaceutical compositions and methods of making same |
| US20130023550A1 (en) * | 2010-05-05 | 2013-01-24 | Glaxo Wellcome Manufacturing Pte, Ltd | Pharmaceutical compositions and methods of making same |
-
2011
- 2011-05-03 TW TW100115488A patent/TW201206908A/zh unknown
- 2011-05-03 UY UY0001033367A patent/UY33367A/es unknown
- 2011-05-03 AR ARP110101514A patent/AR081364A1/es unknown
- 2011-05-05 ES ES11778348.0T patent/ES2519615T3/es active Active
- 2011-05-05 CN CN2011800333447A patent/CN102970871A/zh active Pending
- 2011-05-05 JP JP2013509268A patent/JP5835717B2/ja not_active Expired - Fee Related
- 2011-05-05 BR BR112012028291A patent/BR112012028291A2/pt not_active IP Right Cessation
- 2011-05-05 WO PCT/US2011/035363 patent/WO2011140343A1/en not_active Ceased
- 2011-05-05 NZ NZ603411A patent/NZ603411A/en not_active IP Right Cessation
- 2011-05-05 US US13/101,689 patent/US20110281901A1/en not_active Abandoned
- 2011-05-05 MX MX2012012837A patent/MX2012012837A/es active IP Right Grant
- 2011-05-05 MA MA35417A patent/MA34286B1/fr unknown
- 2011-05-05 KR KR1020127031739A patent/KR20130071434A/ko not_active Withdrawn
- 2011-05-05 PH PH1/2012/502159A patent/PH12012502159A1/en unknown
- 2011-05-05 AU AU2011247995A patent/AU2011247995B2/en not_active Ceased
- 2011-05-05 EP EP11778348.0A patent/EP2566331B1/en active Active
- 2011-05-05 CA CA2798386A patent/CA2798386A1/en not_active Abandoned
- 2011-05-05 PE PE2012002115A patent/PE20130217A1/es not_active Application Discontinuation
- 2011-05-05 US US13/133,030 patent/US20120028918A1/en not_active Abandoned
- 2011-05-05 SG SG2012079968A patent/SG185087A1/en unknown
- 2011-05-05 EA EA201291168A patent/EA201291168A1/ru unknown
-
2012
- 2012-10-29 IL IL222751A patent/IL222751A0/en unknown
- 2012-10-31 CL CL2012003075A patent/CL2012003075A1/es unknown
- 2012-11-01 CR CR20120556A patent/CR20120556A/es unknown
- 2012-11-02 DO DO2012000281A patent/DOP2012000281A/es unknown
- 2012-11-02 ZA ZA2012/08265A patent/ZA201208265B/en unknown
- 2012-12-05 CO CO12221016A patent/CO6640262A2/es not_active Application Discontinuation
-
2015
- 2015-05-06 US US14/705,298 patent/US20150231265A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PH12012502159A1 (en) | 2013-02-04 |
| IL222751A0 (en) | 2012-12-31 |
| NZ603411A (en) | 2014-10-31 |
| EP2566331B1 (en) | 2014-09-03 |
| WO2011140343A1 (en) | 2011-11-10 |
| DOP2012000281A (es) | 2013-05-31 |
| UY33367A (es) | 2011-10-31 |
| EP2566331A1 (en) | 2013-03-13 |
| MX2012012837A (es) | 2013-01-24 |
| SG185087A1 (en) | 2012-12-28 |
| HK1175947A1 (en) | 2013-07-19 |
| AR081364A1 (es) | 2012-08-29 |
| AU2011247995A1 (en) | 2012-12-13 |
| CA2798386A1 (en) | 2011-11-10 |
| EP2566331A4 (en) | 2013-09-18 |
| KR20130071434A (ko) | 2013-06-28 |
| US20120028918A1 (en) | 2012-02-02 |
| TW201206908A (en) | 2012-02-16 |
| JP5835717B2 (ja) | 2015-12-24 |
| US20110281901A1 (en) | 2011-11-17 |
| JP2013525501A (ja) | 2013-06-20 |
| BR112012028291A2 (pt) | 2015-09-15 |
| US20150231265A1 (en) | 2015-08-20 |
| MA34286B1 (fr) | 2013-06-01 |
| AU2011247995B2 (en) | 2014-07-31 |
| CN102970871A (zh) | 2013-03-13 |
| CL2012003075A1 (es) | 2013-03-08 |
| ZA201208265B (en) | 2013-07-31 |
| ES2519615T3 (es) | 2014-11-07 |
| EA201291168A1 (ru) | 2013-06-28 |
| CR20120556A (es) | 2013-02-20 |
| CO6640262A2 (es) | 2013-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130217A1 (es) | Composiciones farmaceuticas y metodos para su elaboracion | |
| AR089673A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| AR089372A1 (es) | Composiciones de cuidado oral | |
| BR122020001787A8 (pt) | Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| CY1122516T1 (el) | Ετοιμες προς χρηση διατυπωσεις κετορολακης | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| BR112015004984A2 (pt) | formulações aquosas estáveis de adalimumab | |
| AR084285A1 (es) | Composiciones inmunogenicas | |
| ECSP14013324A (es) | Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| NI201300068A (es) | Moduladores del receptor de glucagón | |
| MX2021010046A (es) | Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas. | |
| CL2013002810A1 (es) | Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple. | |
| AR087371A1 (es) | Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos | |
| BR112012022469A2 (pt) | composição amaciante de tecido concentrada líquida. | |
| AR076932A1 (es) | Formulaciones de n-halamina con actividad antimicrobiana aumentada. comprimido desinfectante. metodo para desinfectar. | |
| GT201400027A (es) | Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| PE20200958A1 (es) | Solido liofilizado de copanlisib | |
| ECSP11010998A (es) | Formulación galénica que comprende alisquireno y proceso para su preparación mediante granulación de extrusión fundida | |
| AR103719A1 (es) | Composición líquida tópica para el lavado intrauterino que contiene melatonina | |
| CL2013003137A1 (es) | Composición farmacéutica líquida oral que contiene divalproex sódico (2-15 % p/v de la composición), y uno o más excipientes, cuyo ph es mayor a 6; procedimiento de preparación de la composición que comprende: (a) mezclar hidróxido de sodio en agua purificada, (b) añadir divalproex sódico y excipientes; y (c) ajustar ph sobre 6. | |
| AR068978A1 (es) | N-oxidos de venlafaxina y o-desmetilvenlafaxina como prodrogas | |
| GT201400044A (es) | 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |